z-logo
open-access-imgOpen Access
Gene Therapy and Chronic Pain
Author(s) -
Doris K. Cope,
William R. Lariviere
Publication year - 2006
Publication title -
the scientific world journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.453
H-Index - 93
eISSN - 2356-6140
pISSN - 1537-744X
DOI - 10.1100/tsw.2006.197
Subject(s) - chronic pain , medicine , intensive care medicine , genetic enhancement , medical therapy , pain management , pain therapy , refractory (planetary science) , pharmacotherapy , bioinformatics , physical therapy , surgery , gene , biochemistry , astrobiology , biology , chemistry , physics
Chronic, unremitting pain is perhaps the most common reason that patients seek medical care. In general, conservative techniques, such as medical management, are implemented as first-line therapy. Local anesthesia and lytic procedures, followed by interventional techniques, such as dorsal column stimulation and intrathecal drug delivery systems, are second-line therapies. However, for refractory and severe pain, which is not adequately controlled by other modes of therapy, new emerging options, including molecular or gene therapy, may become more widely utilized as experimental results are translated into clinical options.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom